Gilead announced positive data from the late-stage PURPOSE 1 study evaluating twice-yearly subcutaneous lenacapavir for HIV prevention in cisgender women. At the interim analysis, lenacapavir demonstrated 100% efficacy with zero HIV infections and superiority to both background HIV incidence and once-daily oral Truvada.